Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348289 · ClinicalTrials.gov registry record
PIVO Use for Blood Cultures in the Emergency Department
A clinical trial of Sepsis and Emergency Medicine, sponsored by Intermountain Health Care.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT07348289: Recruiting study of Sepsis and Emergency Medicine, sponsored by Intermountain Health Care.
NCT07348289 is a study of Sepsis and Emergency Medicine that is actively recruiting participants, run by Intermountain Health Care. The registered enrollment target is 10,000 participants, above the 6,454-participant average among 90 other Sepsis trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07348289, a study of Sepsis and Emergency Medicine, is actively recruiting participants, sponsored by Intermountain Health Care.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will implement a protocol for use of the PIVO device for blood culture collection in the emergency department. This protocol utilizes the device in various scenarios to reduce needlesticks while allowing for accurate and appropriate assessment of potential pathogens in the bloodstream. The study team will train staff on use of the device then monitor utilization and contamination rates among emergency department patients.
Primary Outcome
The investigators will assess utilization of the device for blood cultures obtained in the emergency department through review of the medical record and documentation of cases in which PIVO was used for blood cultures as a proportion of all blood cultures obtained.
Conditions Studied
Interventions
- DEVICE PIVO device, a needle-free blood draw device
Study Locations (1)
Utah
- Park City Hospital - Park City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2027-07-31 |
What NCT07348289 shows while recruiting
NCT07348289 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 6,454-participant average among 90 other Sepsis trials with a reported enrollment target (55% higher).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which PIVO device, a needle-free blood draw device is the first listed.
NCT07348289 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT07348289 about?
NCT07348289 is a clinical study titled "PIVO Use for Blood Cultures in the Emergency Department". The investigators will implement a protocol for use of the PIVO device for blood culture collection in the emergency department. This protocol utilizes the device in various scenarios to reduce needlesticks while allowing for accurate and appropriate assessment of potential pathogens in the bloodstr...
What is the current status of trial NCT07348289?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2025-10-01. Estimated completion is 2027-07-31.
What conditions does trial NCT07348289 study?
This clinical trial studies the following conditions: Sepsis, Emergency Medicine, Device Performance.
What interventions are being tested in trial NCT07348289?
The interventions under investigation include: PIVO device, a needle-free blood draw device (DEVICE).
Who is sponsoring clinical trial NCT07348289?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348289 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07348289's enrollment target sits among peer trials
10,000 8th of 90 higher than 82 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI